Cargando…
A Review of Omacetaxine: A Chronic Myeloid Leukemia Treatment Resurrected
The paradigm of targeted therapy was pioneered for chronic myeloid leukemia (CML). The advent of tyrosine kinase inhibitors (TKIs) has led to marked improvements in responses and overall survival; however, there is still a subset of patients that are either resistant through a multitude of mechanism...
Autores principales: | Winer, Eric S., DeAngelo, Daniel J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7359993/ https://www.ncbi.nlm.nih.gov/pubmed/32700137 http://dx.doi.org/10.1007/s40487-018-0058-6 |
Ejemplares similares
-
Omacetaxine mepesuccinate in the treatment of intractable chronic myeloid leukemia
por: Chen, Yaoyu, et al.
Publicado: (2014) -
Homoharringtonine and omacetaxine for myeloid hematological malignancies
por: Lü, Shuqing, et al.
Publicado: (2014) -
Omacetaxine Mepesuccinate: A New Treatment Option for Patients With Chronic Myelogenous Leukemia
por: Kurtin, Sandra E., et al.
Publicado: (2013) -
Incidence and management of myelosuppression in patients with chronic- and accelerated-phase chronic myeloid leukemia treated with omacetaxine mepesuccinate
por: Akard, Luke, et al.
Publicado: (2015) -
Inhibitory Effects of Omacetaxine on Leukemic Stem Cells and BCR-ABL-Induced Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia in Mice
por: Chen, Yaoyu, et al.
Publicado: (2009)